The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The efficacy of olutasidenib in AML following venetoclax failure
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the safety and efficacy of olutasidenib, an IDH inhibitor, in patients with acute myeloid leukemia (AML) who experience venetoclax failure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
